Trial Design
ONCOLOGY
This is a prospective, multicenter, interventional, comparative, randomized controlled trial involving a total of 15 institutions in South Korea, of which the Asan Medical Center (Seoul, South Korea) will serve as the leading institution. This study was approved by the institutional review board of Asan Medical Center (approval ID: 2022–1674, approval date December 6, 2022) and is registered in ClinicalTrial.gov (identifier number: NCT05669872). Informed consent will be obtained from all patients before participation.The study schema is shown in Study schema. (CC)RT, (concurrent chemo-) radiation therapy; KGSO, Korean Society of Gynecologic Oncology; PBM, patient blood management.